HAL-Paris 13
Not a member yet
33893 research outputs found
Sort by
Images plurielles : exportation, circulation et réception du cinéma soviétique en France (1924-1939)
No full textInternational audienc
Genome contamination may lead to an overestimation of horizontal gene transfer inferences
No full textInternational audienc
Hybrid Polysaccharide/Magnetite Microgels for Drug‐Free Magnetically Targeted Photothermal Thrombolysis
No full textInternational audienceCardiovascular diseases are the leading cause of death worldwide, primarily due to ischemic events caused by thrombus formation, such as ischemic heart disease and stroke. Current treatments face significant limitations: mechanical thrombectomy lacks accessibility, while fibrinolytic drugs cause severe adverse effects and show limited efficacy. Local hyperthermia may offer a broader mechanism of action, targeting not only the fibrin scaffold but also other clot components. In this work, we present a fully drug‐free strategy based on hybrid microparticles (HPs) composed of magnetite nanoparticles (MNPs) assembled within cross‐linked dextran microgels, for magnetically targeted photo‐thermal therapy. HPs are synthesized through inverse emulsion cross‐linking using biocompatible materials. They exhibit micrometer injectable size, low dispersity, high colloidal stability and excellent biocompatibility. Magnetic coupling of ≈10 5 MNPs within each HP generates a strong magnetic macromoment (≈10 − 1 1 emu), enabling efficient magnetic targeting, both in vitro and in vivo. This feature is accompanied by high photo‐thermal conversion efficiency (38%). The determination of a thrombolytic temperature window enables in vitro photo‐thermal thrombolysis, while in vivo application on a murine thrombus model leads to significant photo‐thermal clot reduction (−32%), without any pharmaceutical agent. These findings highlight the potential of magnetically coupled magnetite nanoparticles for drug‐free targeted photo‐thermal thrombolysis
Sustained Increase in Pediatric Mastoiditis in the Post-COVID-19 Era: A 9-Year Interrupted Time-Series Analysis Based on National Data
No full textInternational audienceObjective To assess the impact of COVID-19 pandemic-related non-pharmaceutical interventions (NPI) on the incidence of mastoiditis cases, causative pathogens, and associated complications in children. Study designWe conducted a population-based interrupted time-series analysis using national surveillance data from France between January 2016 and December 2024. All hospitalized mastoiditis cases among individuals younger than 18 years in France were included. The main outcome was the monthly incidence of mastoiditis cases, analyzed using quasi-Poisson regression models, accounting for seasonality. ResultsWe included 7390 hospitalized cases of mastoiditis in children. Following a decrease in the incidence of mastoiditis by 58.9% (95% CI: 68.2% to 46.9%, P < .001) during the strict NPI period, we observed an increase of 71.7% (95% CI: 26.4% to 133.3%, P < .001) in the post-NPI period compared with the expected trend without NPI. The proportions of complicated cases and those requiring surgery remained stable over time. By pathogen, the most important increase in the post-NPI period was observed among mastoiditis caused by Streptococcus pyogenes (+627.8%, 95% CI: +269.1% to +1335.0%, P < .001), followed by Streptococcus pneumoniae (+135.6%, 95% CI: +20.5% to +360.6%, P = .012) and Haemophilus influenzae (+124.3%, -17.0% to +506.0%, P = .111). ConclusionsIn this 9-year population-based national study, we observed a sustained increase in the incidence and etiology of mastoiditis in children during the post-COVID-19 period. We hypothesize that these changes, associated with NPI during the pandemic and lifting postpandemic, reflect consequences that should be considered in the management of future pandemics. (</div
Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma
No full textInternational audienc
Real-life impact of clinical metagenomics in the intensive care unit: a multicenter retrospective study in greater paris area hospitals
No full textInternational audienc
Assessing congestion in heart failure: tools are already available, but integration is key
No full textInternational audienceCongestion represents the principal clinical manifestation and hemodynamic hallmark of heart failure (HF), reflecting elevated cardiac filling pressures. It remains the leading cause of HF hospitalization and is consistently associated with adverse outcomes across all stages of the disease. Despite its major prognostic implications, the assessment of congestion remains suboptimal in both acute and chronic settings, with up to one-third of patients discharged while still fluid overloaded. This review, developed following the Critical Care Clinical Trialists (3CT) Workshop 2025, summarizes current and well-established approaches for evaluating congestion, and introduces new and emerging tools that may simplify its recognition and management while allowing for a more accurate and timely assessment. We further discuss how integrating clinical, imaging, hemodynamic, and patient-centered strategies may enable optimal congestion management and support a paradigm shift from reactive decongestion to proactive, individualized care. This review, inspired by the dedicated session "Assessing Congestion in Heart Failure -Tools Are Already Available" held at 3CT, Critical Care Clinical Trialists Workshop meeting in June 2025 and involving clinical trialists, patients, clinicians, as well as representatives from regulatory agency, government, and industry representatives, outlines the current landscape of congestion assessment. We discuss established and emerging approaches that may enable earlier recognition and patient-driven strategies, ultimately shifting management from reactive decongestion to proactive, personalized care.</div
Prognostic Impact of Recreational Drug Use on 1-Year Outcomes in NSTEMI and STEMI Patients
No full textInternational audienceBackground: Recreational drug use is increasingly associated with adverse outcomes in acute coronary syndrome (ACS) patients, but differences in long-term outcomes between ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction are not well defined.Objective: The authors evaluated the association between recreational drug use and major adverse cardiovascular events (MACE) 1 year after intensive cardiac care unit (ICCU) admission in ACS patients.Methods: The Addiction in Intensive Cardiac Care Units study systematically screened all patients admitted to ICCUs across 39 French centers (April 7-22, 2021) via prospective urinary testing. The primary outcome was MACE, defined as cardiovascular death, nonfatal myocardial infarction, or stroke. One-year follow-up was collected through clinical visits or direct contact between patients and cardiologists, concluding in June 2022. Outcomes were adjudicated by an independent cardiology committee. The prognostic impact of recreational drug use on MACE was assessed using multivariable Cox proportional hazards models, validated by propensity matching.Results: Of 712 ACS patients, 13.5% had recreational drug detection. At 1 year, MACE occurred in 7.0%, with higher rates among drug-positive vs drug-negative patients (12.5% vs 6.2%). Recreational drug use was associated with increased MACE (HR: 2.70; 95% CI: 1.30-5.57; P = 0.013). This association was significant in STEMI (HR: 4.11; 95% CI: 1.60-10.5; P = 0.005) but not in non-ST-elevation myocardial infarction patients. Propensity matching confirmed this in STEMI patients (HR: 3.39; 95% CI: 1.19-9.62; P = 0.022).Conclusions: Recreational drug use was associated with increased 1-year MACE risk in ACS patients, particularly STEMI, supporting routine drug screening
Clinical Phenotypes of Critically Ill Patients with COVID-19 Infected with Omicron: A Nationwide Prospective Cohort Study
No full textInternational audienceINTRODUCTION: The clinical presentation of critically ill patients with coronavirus disease 2019 (COVID-19) has evolved significantly with the emergence of the Omicron variant. Current intensive care unit (ICU) admissions involve patients with diverse comorbidities and immune statuses, highlighting the need to redefine homogeneous phenotypic subgroups within this population. This study aimed to characterize distinct clinical phenotypes among critically ill patients with COVID-19 and acute respiratory failure. METHODS: This multicenter prospective substudy of the SEVARVIR cohort included adult patients from 39 French ICUs between December 2021 and October 2024 with acute respiratory failure and infected with the Omicron variant. Clustering analysis was conducted using Kohonen’s self-organizing maps (SOMs) and validated with ClinTrajan, two unsupervised clustering methods, to identify homogeneous patient phenotypes. RESULTS: During the study period, 777 patients with Omicron infection were included, and 7 distinct clinical clusters were identified. Clusters 1 and 2 included patients with metabolic and cardiovascular comorbidities. Cluster 3 featured younger, mildly ill patients with isolated chronic respiratory failure, while cluster 4 comprised older male patients with isolated respiratory failure. Cluster 5 included patients with isolated hematologic malignancies, cluster 6 patients with multiorgan failure, and cluster 7 organ transplant recipients, with high severity scores and impaired renal function. ICU management varied substantially across clusters. Patients in clusters 5 and 7 had the highest requirements for organ support, with frequent use of invasive mechanical ventilation, vasopressors (cluster 6), and renal replacement therapy (cluster 7). Dexamethasone and tocilizumab were most commonly prescribed in cluster 4 (91.3% and 30.2%, respectively). Mortality at day 28 varied significantly across clusters, ranging from 13.1% in cluster 3 to 41.1% in cluster 6. CONCLUSIONS: This clustering analysis highlights, for the first time, the clinical heterogeneity of critically ill patients infected with Omicron, identifying seven distinct clusters with varying clinical presentations, management strategies and outcomes. These findings underscore the relevance of a phenotype-driven approach to support personalized treatment strategies and guide future clinical trials. TRIAL REGISTRATION: Clinicaltrials.gov, NCT05162508. A Graphical Abstract is available for this article